Parenchymal-sparing hepatectomy with hepatic vein resection and reconstruction.

Autor:	Apers T; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium., Hendrikx B; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium., Bracke B; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium., Hartman V; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium., Roeyen G; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium., Ysebaert D; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium., Op de Beeck B; Department of Radiology, Antwerp University Hospital, Edegem, Belgium., Chapelle T; Department of Hepatobiliary and Transplantation Surgery, Antwerp University Hospital, Edegem, Belgium.
Jazyk:	angličtina
Zdroj:	Acta chirurgica Belgica [Acta Chir Belg] 2022 Oct; Vol. 122 (5), pp. 334-340. Date of Electronic Publication: 2021 May 31.
DOI:	10.1080/00015458.2021.1915021
Abstrakt:	Background: Hepatectomy remains the most important treatment modality for most malignant liver tumors. Vascular involvement stays a reason for unresectability or major parenchymal resection. A possible way to avoid this is parenchymal-sparing hepatectomy (PSHX) with vascular resection and reconstruction (HVRR). In this article, we aim to demonstrate the specific role of this technique in avoiding post-hepatectomy liver failure (PHLF). Methods: A retrospective analysis of 10 patients who underwent HVRR was conducted. 99m Technetium-mebrofenin hepatobiliary scintigraphy (HBS) was used to predict the future liver remnant function (FLRF). Calculations were made for each patient to compare HVRR and major hepatectomy (with or without portal vein embolization). Results: In our cohort, there was no perioperative mortality. Two patients suffered a Clavien-Dindo grade 3a complication and none had clinically significant PHLF. Estimated FLRF was significantly higher in HVRR compared to major hepatectomy after portal vein embolization ( p  < .005). Conclusions: Instead of focusing on inducing liver remnant hypertrophy, preserving parenchyma through HVRR can be an interesting treatment strategy. It can be performed with an acceptable operative risk. Calculations of FLRF (using HBS) suggest that this approach is able to reduce the risk for PHLF and related morbidity or mortality.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu